Compare SRTA & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | RZLT |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | 601 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.1M | 326.4M |
| IPO Year | N/A | 2011 |
| Metric | SRTA | RZLT |
|---|---|---|
| Price | $4.50 | $3.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $7.81 | ★ $9.67 |
| AVG Volume (30 Days) | 649.7K | ★ 2.4M |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.27 | N/A |
| Revenue Next Year | $9.09 | N/A |
| P/E Ratio | $9.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.85 | $1.07 |
| 52 Week High | $6.02 | $11.46 |
| Indicator | SRTA | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 57.43 | 59.11 |
| Support Level | $4.23 | $2.87 |
| Resistance Level | $4.69 | $3.66 |
| Average True Range (ATR) | 0.16 | 0.23 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 96.52 | 68.06 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.